BACKGROUND and OBJECTIVES In the era of drug-eluting stents, much comparison was done between paclitaxel-eluting stents (PES) and everolimus-eluting stents (EES). In comparison, there were few studies between everolimus-eluting stents (EES) and sirolimus-eluting stents (SES), but recently many studies are being reported. Still, there are limited studies of comparison between EES and SES in acute myocardial infarction. SUBJECTS and METHODS In 2011, 5694 patients were registered in COREA-AMI (COnvergent REgistry of cAtholic and chonnAm university for AMI) registry. In COREA-AMI, 1079 patients used EES and 578 patients used SES. Patients who used a combination of EES or SES with another stent were excluded. RESULTS In baseline characteristics, HbA1c, hemoglobin, total stent length, mean stent diameter was different between two groups. SES group had a longer total stent length(TSL), larger mean stent diameter(MSD), TSL 28.8짹25.3 vs 15.3짹22.4 (p<0.001), MSD 3.1짹0.7 vs 2.9짹1.1 (p<0.001). Also there was a tendency of SES used more often in LAD lesion, longer total stent length, higher vessel-disease. Using cox-regression analysis, predictor for MACE (death, MI, TLR, TVR) found was mean stent diameter only. Hazard ratio of EES to SES was 1.128 (95% confidence interval 0.733 to 1.737, p=0.584) in multivariate cox-regression. In rates of composite of all cause death, recurrent non-fatal myocardial infarction, and target vessel revascularization, EES was non-inferior to SES. CONCLUSION EES was non-inferior to SES in COREA-AMI registry. A random-controlled trial in acute myocardial infarction could clarify this result.